Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Enanta Pharmaceuticals Inc. manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 pending office actions indicate an active prosecution strategy within the life sciences sector. The focus on Biotechnology & Pharmaceuticals suggests that the company is protecting innovations related to drug development or biological research. Practitioners should note the technical diversity within this technology area.
The 4 pending office actions are distributed across 3 distinct art units and 4 distinct examiners. This distribution shows that every pending action is being reviewed by a different examiner, which requires a tailored approach for each case. The involvement of 3 distinct art units indicates that the company's technology is being examined by several specialized groups at the USPTO. This fragmentation requires careful coordination to ensure consistent arguments across the portfolio.
HEITMEIER, KENDALL NICOLE is the busiest examiner, with 1 busiest examiner pending action. Since each of the 4 distinct examiners holds exactly 1 action, the workload is evenly spread across the portfolio. Practitioners must coordinate their efforts across 3 distinct art units to address the 4 pending office actions. This structure allows for a focused strategy within the 3 distinct art units while managing 4 distinct examiner relationships.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18236560 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | REILLY, SOPHIA JANE | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18236560 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | REILLY, SOPHIA JANE | 5d |
| 18797587 | Processes For The Preparation Of Oxadiazolylamino Benzodiazepine Derivatives | HEITMEIER, KENDALL NICOLE | — |
| 18509403 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | KOSAR, ANDREW D | — |
| 18139506 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1627 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18797587 | Processes For The Preparation Of Oxadiazolylamino Benzodiazepine Derivatives | HEITMEIER, KENDALL NICOLE | — | §102§103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18509403 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | KOSAR, ANDREW D | 1625 | §102 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18236560 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | REILLY, SOPHIA JANE | 1627 | §102§103§112Other | Non-Final OA | 5d | Pending | Aug 22, 2023 |
| 18139506 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ANDERSON, REBECCA L | 1626 | §103 | Final Rejection | — | Pending | Apr 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial